Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2021 | $38.00 → $5.00 | Buy → Hold | Jefferies |
| 12/2/2021 | $45.00 → $5.00 | Buy → Underperform | B of A Securities |
| 12/1/2021 | Outperform → Mkt Perform | William Blair | |
| 12/1/2021 | Buy → Neutral | H.C. Wainwright | |
| 9/20/2021 | $100.00 → $65.00 | Buy | HC Wainwright & Co. |
| 9/9/2021 | $50.00 | Outperform | Robert W. Baird |
| 9/9/2021 | $50.00 | Outperform | Baird |
| 8/4/2021 | $100.00 | Neutral → Buy | HC Wainwright & Co. |
FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 through June 3 in Chicago, IL. Presentation details are as follows: Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Pli
Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED's first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update. "Plinabulin has now been administered to more than 7
FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission ("SEC") on March 27, 2025. The annual report on Form 10-K, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under "Financials & Filings" in the Investors section. The Company will provide
Jefferies downgraded BeyondSpring from Buy to Hold and set a new price target of $5.00 from $38.00 previously
B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously
William Blair downgraded BeyondSpring from Outperform to Mkt Perform
10-Q - BeyondSpring Inc. (0001677940) (Filer)
8-K - BeyondSpring Inc. (0001677940) (Filer)
10-K - BeyondSpring Inc. (0001677940) (Filer)
4 - BeyondSpring Inc. (0001677940) (Issuer)
4 - BeyondSpring Inc. (0001677940) (Issuer)
4 - BeyondSpring Inc. (0001677940) (Issuer)
Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI
FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center), an
New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily Pretreated Patients in 6 different cancersFull data was presented at SITC's 38th Annual Meeting; The Company will host a call at 8:30 a.m. ET today. Dial in: 877-407-0792, conference title: Clinical Significance of Plinabulin SITC Presentation with PI Dr. Steven Lin from MD Anderson NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platfor
SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)
SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)
SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawa
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the "Company"), a BeyondSpring (NASDAQ:BYSI) subsidiary and global research company focused on harnessing and engineering "molecular glues," a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 5
SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin